No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).

about

Pharmacotherapy of Anal Cancer.Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy Treatment of squamous cell carcinoma of the anal canal (SCCA): a new era?

P2860

Q38647761-1C0B7253-51E7-476B-A5A9-DC7EA7DEFDA0 Q38734344-ECBE1C40-8826-4938-9DA2-62D32522034D Q49842285-AD7ECFD3-97D7-4282-8027-80B037258A52

P2860

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).

Item

http://www.wikidata.org/entity/Q39154481

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).

@en

No evidence of NRAS mutation in squamous cell anal carcinoma

@nl

type

Item

label

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).

@en

No evidence of NRAS mutation in squamous cell anal carcinoma

@nl

prefLabel

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).

@en

No evidence of NRAS mutation in squamous cell anal carcinoma

@nl

P1476

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).

@en

P2093

Emanuela Scarpi

http://www.w3.org/2001/XMLSchema#string

Giovanni Luca Frassineti

http://www.w3.org/2001/XMLSchema#string

Jody Corbelli

http://www.w3.org/2001/XMLSchema#string

Laura Capelli

http://www.w3.org/2001/XMLSchema#string

Luca Saragoni

http://www.w3.org/2001/XMLSchema#string

Mario Scartozzi

http://www.w3.org/2001/XMLSchema#string

Massimo Giannini

http://www.w3.org/2001/XMLSchema#string

Maurizio Puccetti

http://www.w3.org/2001/XMLSchema#string

Paola Ulivi

http://www.w3.org/2001/XMLSchema#string

Stefano Tamberi

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC)

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response

Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma.

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas

Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy

P2888

srep37621

P304

37621

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SREP37621

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andrea Casadei Gardini

P577

2016-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27886225

http://www.w3.org/2001/XMLSchema#string

P932

5122846

http://www.w3.org/2001/XMLSchema#string

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).

about

P2860

P2860

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P50

P577

P698

P932